XNAS
MLTX
Market cap2.15bUSD
Apr 10, Last price
33.97USD
1D
-5.59%
1Q
-26.65%
IPO
222.91%
Name
MoonLake Immunotherapeutics
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-120.68b
L+335,054.64%
CFO
-116.59b
L+272,439.17%
Earnings
May 05, 2025
Profile
Helix Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses or entities. The company was founded in 2020 and is based in Boston, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 143,091,082 | 54,136 | 65,074 | ||
Unusual Expense (Income) | |||||
NOPBT | (143,091,082) | (54,136) | (65,074) | ||
NOPBT Margin | |||||
Operating Taxes | (282,199) | 94 | 36 | ||
Tax Rate | |||||
NOPAT | (142,808,883) | (54,231) | (65,110) | ||
Net income | (120,680,002) 335,054.64% | (36,007) -44.18% | (64,506) 20.25% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 52,540 | 482,454 | 4 | ||
BB yield | -1.54% | -16.26% | 0.00% | ||
| Debt | |||||
Debt current | 1,372 | 1,306 | 154 | ||
Long-term debt | 4,287 | 6,306 | 412 | ||
Deferred revenue | |||||
Other long-term liabilities | 2,076,824 | 583 | 282 | ||
Net debt | (448,021,690) | (503,396) | (71,550) | ||
| Cash flow | |||||
Cash from operating activities | (116,587,263) | (42,778) | (55,894) | ||
CAPEX | (519,520) | (285) | (16) | ||
Cash from investing activities | (205,595,299) | (25,184) | (32,341) | ||
Cash from financing activities | 51,311,708 | 479,702 | 119,693 | ||
FCF | (143,767,872) | (57,848) | (65,396) | ||
| Balance | |||||
Cash | 448,027,349 | 511,008 | 72,115 | ||
Long term investments | |||||
Excess cash | 448,027,349 | 511,008 | 72,115 | ||
Stockholders' equity | (235,581,420) | (96,478) | (60,426) | ||
Invested Capital | 691,052,213 | 614,359 | 129,647 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 62,870 | 49,123 | 29,361 | ||
Price | 54.15 -10.33% | 60.39 475.14% | 10.50 6.17% | ||
Market cap | 3,404,423 14.76% | 2,966,510 862.23% | 308,294 297.57% | ||
EV | (444,610,700) | 2,480,929 | 256,613 | ||
EBITDA | (141,706,353) | (54,123) | (65,061) | ||
EV/EBITDA | 3.14 | ||||
Interest | 592 | ||||
Interest/NOPBT | |||||